Back to News

Withdrawal of Belviq and Belviq XR by Eisai

February 28, 2020

The FDA announced the request to voluntarily withdraw Belviq, Belviq XR (lorcaserin) from the U.S. market because a safety clinical trial showed an increased occurrence of cancer. Eisai, the manufacturer, has submitted a request to voluntarily withdraw the drug.

Clinical Services will be conducting a drug recall mailing to potentially impacted members and providers. 

 

Property Value
 Products  Belviq, Belviq XR
 Manufacturer  Eisai
 Withdrawal identification date  02/13/2020
 Affected NDCs  62856-0529-60, 62856-0535-30
 Look back period  10/16/2019  - 2/13/2020
 Target population for clinical mailing  All
 Mailing type  Members and Providers
 Data release  SS00005114
 Fulfillment due date for NCQA compliance  On or before: 3/4/2020